Bloating in gastroparesis: Severity, impact, and associated factors

William L. Hasler, Laura Wilson, Henry P. Parkman, Linda Nguyen, Thomas L. Abell, Kenneth L. Koch, Pankaj Jay Pasricha, William J. Snape, Gianrico Farrugia, Linda A Lee, James A Tonascia, Aynur Unalp-Arida, Frank Hamilton

Research output: Contribution to journalArticle

Abstract

Objectives: Bloating is commonly reported in gastroparesis, but its prevalence, impact, and associated factors are uninvestigated. We aimed to quantify the prevalence of bloating in gastroparesis and relate its severity to clinical factors and quality of life. Methods: Survey, examination, and scintigraphy data were compared in 335 gastroparesis patients from 6 centers of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Gastroparesis Clinical Research Consortium. Bloating severity was stratified using Gastroparesis Cardinal Symptom Index (GCSI) bloating subscale scores. Results: Bloating severity of at least mild (GCSI ≥2) and severe (GCSI ≥4) grades were reported by 76 and 41% of patients, respectively. Bloating severity related to female gender (P0.05). Disease-specific quality of life and general measures of well-being were progressively impaired with increasing bloating severity (P=0.01). Probiotic use (P=0.03) and use of antidepressants with significant norepinephrine reuptake inhibitor activity (P=0.045) use related to bloating severity; antiemetic use trended higher with worsening bloating (P=0.06). Conclusions: Bloating is prevalent in gastroparesis and is severe in many individuals. Bloating severity relates to female gender, body weight, and intensity of other symptoms. The symptom impairs quality of life but is not influenced by gastric emptying rates. Antiemetics, probiotics, and antidepressants with significant norepinephrine reuptake inhibitor activity may affect reports of bloating. These findings provide insight into this underappreciated symptom of gastroparesis.

Original languageEnglish (US)
Pages (from-to)1492-1502
Number of pages11
JournalAmerican Journal of Gastroenterology
Volume106
Issue number8
DOIs
StatePublished - Aug 2011

Fingerprint

Gastroparesis
Antiemetics
Quality of Life
Probiotics
Antidepressive Agents
Norepinephrine
National Institute of Diabetes and Digestive and Kidney Diseases (U.S.)
Gastric Emptying
Radionuclide Imaging
Body Weight

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Hasler, W. L., Wilson, L., Parkman, H. P., Nguyen, L., Abell, T. L., Koch, K. L., ... Hamilton, F. (2011). Bloating in gastroparesis: Severity, impact, and associated factors. American Journal of Gastroenterology, 106(8), 1492-1502. https://doi.org/10.1038/ajg.2011.81

Bloating in gastroparesis : Severity, impact, and associated factors. / Hasler, William L.; Wilson, Laura; Parkman, Henry P.; Nguyen, Linda; Abell, Thomas L.; Koch, Kenneth L.; Pasricha, Pankaj Jay; Snape, William J.; Farrugia, Gianrico; Lee, Linda A; Tonascia, James A; Unalp-Arida, Aynur; Hamilton, Frank.

In: American Journal of Gastroenterology, Vol. 106, No. 8, 08.2011, p. 1492-1502.

Research output: Contribution to journalArticle

Hasler, WL, Wilson, L, Parkman, HP, Nguyen, L, Abell, TL, Koch, KL, Pasricha, PJ, Snape, WJ, Farrugia, G, Lee, LA, Tonascia, JA, Unalp-Arida, A & Hamilton, F 2011, 'Bloating in gastroparesis: Severity, impact, and associated factors', American Journal of Gastroenterology, vol. 106, no. 8, pp. 1492-1502. https://doi.org/10.1038/ajg.2011.81
Hasler, William L. ; Wilson, Laura ; Parkman, Henry P. ; Nguyen, Linda ; Abell, Thomas L. ; Koch, Kenneth L. ; Pasricha, Pankaj Jay ; Snape, William J. ; Farrugia, Gianrico ; Lee, Linda A ; Tonascia, James A ; Unalp-Arida, Aynur ; Hamilton, Frank. / Bloating in gastroparesis : Severity, impact, and associated factors. In: American Journal of Gastroenterology. 2011 ; Vol. 106, No. 8. pp. 1492-1502.
@article{8042d15c3f1546c3b2365fb3d93018c3,
title = "Bloating in gastroparesis: Severity, impact, and associated factors",
abstract = "Objectives: Bloating is commonly reported in gastroparesis, but its prevalence, impact, and associated factors are uninvestigated. We aimed to quantify the prevalence of bloating in gastroparesis and relate its severity to clinical factors and quality of life. Methods: Survey, examination, and scintigraphy data were compared in 335 gastroparesis patients from 6 centers of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Gastroparesis Clinical Research Consortium. Bloating severity was stratified using Gastroparesis Cardinal Symptom Index (GCSI) bloating subscale scores. Results: Bloating severity of at least mild (GCSI ≥2) and severe (GCSI ≥4) grades were reported by 76 and 41{\%} of patients, respectively. Bloating severity related to female gender (P0.05). Disease-specific quality of life and general measures of well-being were progressively impaired with increasing bloating severity (P=0.01). Probiotic use (P=0.03) and use of antidepressants with significant norepinephrine reuptake inhibitor activity (P=0.045) use related to bloating severity; antiemetic use trended higher with worsening bloating (P=0.06). Conclusions: Bloating is prevalent in gastroparesis and is severe in many individuals. Bloating severity relates to female gender, body weight, and intensity of other symptoms. The symptom impairs quality of life but is not influenced by gastric emptying rates. Antiemetics, probiotics, and antidepressants with significant norepinephrine reuptake inhibitor activity may affect reports of bloating. These findings provide insight into this underappreciated symptom of gastroparesis.",
author = "Hasler, {William L.} and Laura Wilson and Parkman, {Henry P.} and Linda Nguyen and Abell, {Thomas L.} and Koch, {Kenneth L.} and Pasricha, {Pankaj Jay} and Snape, {William J.} and Gianrico Farrugia and Lee, {Linda A} and Tonascia, {James A} and Aynur Unalp-Arida and Frank Hamilton",
year = "2011",
month = "8",
doi = "10.1038/ajg.2011.81",
language = "English (US)",
volume = "106",
pages = "1492--1502",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Bloating in gastroparesis

T2 - Severity, impact, and associated factors

AU - Hasler, William L.

AU - Wilson, Laura

AU - Parkman, Henry P.

AU - Nguyen, Linda

AU - Abell, Thomas L.

AU - Koch, Kenneth L.

AU - Pasricha, Pankaj Jay

AU - Snape, William J.

AU - Farrugia, Gianrico

AU - Lee, Linda A

AU - Tonascia, James A

AU - Unalp-Arida, Aynur

AU - Hamilton, Frank

PY - 2011/8

Y1 - 2011/8

N2 - Objectives: Bloating is commonly reported in gastroparesis, but its prevalence, impact, and associated factors are uninvestigated. We aimed to quantify the prevalence of bloating in gastroparesis and relate its severity to clinical factors and quality of life. Methods: Survey, examination, and scintigraphy data were compared in 335 gastroparesis patients from 6 centers of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Gastroparesis Clinical Research Consortium. Bloating severity was stratified using Gastroparesis Cardinal Symptom Index (GCSI) bloating subscale scores. Results: Bloating severity of at least mild (GCSI ≥2) and severe (GCSI ≥4) grades were reported by 76 and 41% of patients, respectively. Bloating severity related to female gender (P0.05). Disease-specific quality of life and general measures of well-being were progressively impaired with increasing bloating severity (P=0.01). Probiotic use (P=0.03) and use of antidepressants with significant norepinephrine reuptake inhibitor activity (P=0.045) use related to bloating severity; antiemetic use trended higher with worsening bloating (P=0.06). Conclusions: Bloating is prevalent in gastroparesis and is severe in many individuals. Bloating severity relates to female gender, body weight, and intensity of other symptoms. The symptom impairs quality of life but is not influenced by gastric emptying rates. Antiemetics, probiotics, and antidepressants with significant norepinephrine reuptake inhibitor activity may affect reports of bloating. These findings provide insight into this underappreciated symptom of gastroparesis.

AB - Objectives: Bloating is commonly reported in gastroparesis, but its prevalence, impact, and associated factors are uninvestigated. We aimed to quantify the prevalence of bloating in gastroparesis and relate its severity to clinical factors and quality of life. Methods: Survey, examination, and scintigraphy data were compared in 335 gastroparesis patients from 6 centers of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Gastroparesis Clinical Research Consortium. Bloating severity was stratified using Gastroparesis Cardinal Symptom Index (GCSI) bloating subscale scores. Results: Bloating severity of at least mild (GCSI ≥2) and severe (GCSI ≥4) grades were reported by 76 and 41% of patients, respectively. Bloating severity related to female gender (P0.05). Disease-specific quality of life and general measures of well-being were progressively impaired with increasing bloating severity (P=0.01). Probiotic use (P=0.03) and use of antidepressants with significant norepinephrine reuptake inhibitor activity (P=0.045) use related to bloating severity; antiemetic use trended higher with worsening bloating (P=0.06). Conclusions: Bloating is prevalent in gastroparesis and is severe in many individuals. Bloating severity relates to female gender, body weight, and intensity of other symptoms. The symptom impairs quality of life but is not influenced by gastric emptying rates. Antiemetics, probiotics, and antidepressants with significant norepinephrine reuptake inhibitor activity may affect reports of bloating. These findings provide insight into this underappreciated symptom of gastroparesis.

UR - http://www.scopus.com/inward/record.url?scp=79961028860&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79961028860&partnerID=8YFLogxK

U2 - 10.1038/ajg.2011.81

DO - 10.1038/ajg.2011.81

M3 - Article

C2 - 21483459

AN - SCOPUS:79961028860

VL - 106

SP - 1492

EP - 1502

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 8

ER -